Axiom Worldwide, Inc. v. Excite Medical Corp.

591 F. App'x 767
CourtCourt of Appeals for the Eleventh Circuit
DecidedNovember 17, 2014
Docket13-13900
StatusUnpublished
Cited by7 cases

This text of 591 F. App'x 767 (Axiom Worldwide, Inc. v. Excite Medical Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Axiom Worldwide, Inc. v. Excite Medical Corp., 591 F. App'x 767 (11th Cir. 2014).

Opinion

ROSENBAUM, Circuit Judge:

Billy Preston and Bruce Fisher could have been talking about Appellants Excite Medical Corporation (“EMC”) and Saleem N. Musallam’s trademark rights for Axiom Worldwide, Inc.’s DRX9000, DRX9000C, and DRX9500 medical products when they wrote the lyric, “Nothin’ from nothin’ leaves nothin’.” 1 EMC and Musallam claim their trademark rights in the products at issue based on their relationship with HTRD Group Hong Kong Limited, which, in turn, claims its trademark rights from Michael Leutgert and Associates, which, in turn, succeeded to all of the interests of Axiom Worldwide, LLC (“Axiom, LLC”).

The problem is, Axiom, LLC, never owned trademark rights in the medical products. Instead, Appellee, the separate company Axiom Worldwide, Inc. (“Axiom, Inc.”), owns and has always owned the trademarks. So Axiom, LLC, started with nothing in the trademark department and passed that same nothing down, all the way to Appellants. As a result, when Axiom, Inc., filed suit against Appellants and HTRD for, among other claims, trademark infringement, the district court decided against Appellants and ordered Appellants to pay Axiom, Inc., $1.82 million in lost-profit damages stemming from Appellants’ infringement of Axiom, Inc.’s trademarks.

Also, during the course of the proceedings, the district court sanctioned Appellants for discovery misconduct by striking their pleadings and entering default judgments on several claims. On appeal, EMC and Musallam contest the determination that they do not enjoy trademark rights, the awarding of and amount of damages, and the discovery sanctions. Because we agree with the district court (and Billy Preston and Bruce Fisher, for that matter) that nothin’ from nothin’ leaves nothin’, 2 and because we find no error in any of the district court’s other challenged rulings, we affirm.

I.

A. History of the Prior Litigation

In order to address the parties’ issue-preclusion dispute, it is first necessary to review the circumstances that gave rise to and were considered during the prior litigation involving the trademark-ownership issue. Axiom, Inc., is a Florida corporation that develops, manufactures, and sells medical products around the world. Axiom, Inc.’s “flagship” product is the DRX9000, a device that treats back pain. Axiom, Inc., also developed and marketed a similar device for treating neck pain called the DRX9000C or DRX9500. Between 2003 and 2005, Axiom, Inc., registered five trademarks related to these devices with the U.S. Patent and Trademark Office (“USPTO”).

In December 2005, Axiom, LLC, was established in connection with a proposed *769 sale of assets to a group of investors. Axiom, Inc., executed a Warranty Bill of Sale on February 19, 2007, transferring to Axiom, LLC, its “right, title and interest in and to all of [Axiom, Inc.’s] raw materials inventory, finished goods inventory, computer equipment, leasehold improvements, machinery, equipment, furniture, fixtures and goodwill.” The Bill of Sale was made retroactive to January B, 2006.

Following the creation of Axiom, LLC, both that company and Axiom, Inc., “became embroiled in a myriad of litigation fronts from competitors and regulatory bodies alike.” In one suit, styled North American Medical Corp. v. Axiom Worldwide, Inc., No. 1:06-cv-01678-CCH (N.D.Ga. July 14, 2006) (the “Atlanta Case”), North American Medical Corporation (“North American”), a competing manufacturer of spinal-pain medical devices, sued Axiom, Inc., for, among other things, trademark infringement. North American’s suit was filed on July 14, 2006 — prior to the execution of the bill of sale, but after its effective date. Eventually, North American amended its complaint to add Axiom, LLC, as a party, and on January 27, 2009, Axiom, LLC, answered, asserting a variety of counterclaims — including a claim for infringement of its trademarks — against North American. While Axiom, Inc., was a co-defendant in North American’s original claims, it was not a party to Axiom, LLC’s counterclaim against North American.

North American moved for partial summary judgment, arguing on the trademark issue that Axiom, LLC, lacked standing because Axiom, Inc., never transferred the trademarks to the LLC. Axiom, LLC, responded by arguing, among other things, that the bill of sale was intended to convey all of Axiom, Inc.’s assets to the LLC, including the trademarks. On June 25, 2010, the district court in Atlanta ruled in favor of North American, noting both that the USPTO records current at the time indicated Axiom, Inc., was the owner of the trademarks, and that “the 2007 Warranty Bill of Sale did not, by its terms, transfer Axiom Inc.’s trademarks, or any intellectual property rights, to Axiom LLC.” N. Am. Med. Corp. v. Axiom Worldwide, Inc., No. 1:06-ev-01678-CCH, slip op. at 8-9 (N.D.Ga. June 25, 2010) (ECF No. 846). Eventually, the parties voluntarily dismissed the Atlanta Case, but in doing so, the parties explicitly stipulated (and the court adopted) that the summary judgment order against Axiom, LLC, would remain binding. Id., slip op. at 2 (N.D.Ga. Apr. 13, 2012) (ECF No. 974). In sum, at the conclusion of the Atlanta Case, Axiom, Inc., was the recognized owner of the trademarks at issue here..

B. The Succession of Interests

In September 2008, Axiom, LLC, borrowed money from Progress Bank, N.A., and, in exchange, granted Progress Bank a security interest in all of Axiom, LLC’s assets. Progress Bank eventually sued Axiom, LLC, in Florida state court, seeking to foreclose on the assets after Axiom, LLC, defaulted on the loan. Progress Bank obtained a judgment in its favor, but that judgment was reversed on jurisdictional grounds. Axiom, LLC, then filed a petition for the “Assignment for Benefit of Creditors to Michael Luetgert and Associates,” seeking assignment of all of Axiom, LLC’s assets to Luetgert. Leutgert was then authorized to sell Axiom, LLC’s assets to Progress Bank.

On July 2, 2010, Luetgert executed a bill of sale to transfer all assets in his possession — that is, all of the assets formerly belonging to Axiom, LLC — to Progress Bank. Axiom, Inc., was not involved in connection with any of these proceedings. Two weeks later, Progress Bank sold all of *770 the assets it acquired from Luetgert to HTRD Group Hong Kong Limited (“HTRD”), a foreign corporation authorized to do business in Florida, via an “as is” and “where is” “Quit Claim Bill of Sale and Assignment.” HTRD, a co-defendant with EMC and Musallam below, admits that it was aware of the Atlanta Case and the summary-judgment order regarding trademark ownership at the time it executed the quitclaim bill of sale. HTRD nevertheless filed paperwork with the USPTO to transfer the trademarks to its name.

Although the full scope of the commercial relationship between HTRD and the two Appellants, EMC and Musallam, is not entirely clear, it is undisputed that HTRD and EMC jointly filed paperwork with the Food and Drug Administration allowing EMC to become a “contract manufacturer” for the DRX devices. EMC is an authorized distributor of the DRX devices for HTRD. Musallam also testified that he gets his rights to sell the DRX machines from HTRD.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
591 F. App'x 767, Counsel Stack Legal Research, https://law.counselstack.com/opinion/axiom-worldwide-inc-v-excite-medical-corp-ca11-2014.